Literature DB >> 28259764

Feasibility of Freeze-Drying Oil-in-Water Emulsion Adjuvants and Subunit Proteins to Enable Single-Vial Vaccine Drug Products.

Vidyashankara Iyer1, Corinne Cayatte2, Jason D Marshall2, Jenny Sun3, Kirsten Schneider-Ohrum2, Sean K Maynard2, Gaurav Manohar Rajani2, Angie Snell Bennett2, Richard L Remmele3, Steve M Bishop3, Michael P McCarthy2, Bilikallahalli K Muralidhara3.   

Abstract

To generate potent vaccine responses, subunit protein antigens typically require coformulation with an adjuvant. Oil-in-water emulsions are among the most widely investigated adjuvants, based on their demonstrated ability to elicit robust antibody and cellular immune responses in the clinic. However, most emulsions cannot be readily frozen or lyophilized, on account of the risk of phase separation, and may have a deleterious effect on protein antigen stability when stored long term as a liquid coformulation. To circumvent this, current emulsion-formulated vaccines generally require a complex multivial presentation with obvious drawbacks, making a single-vial presentation for such products highly desirable. We describe the development of a stable, lyophilized squalene emulsion adjuvant through innovative formulation and process development approaches. On reconstitution, freeze-dried emulsion preparations were found to have a minimal increase in particle size of ∼20 nm and conferred immunogenicity in BALB/c mice similar in potency to freshly prepared emulsion coformulations in liquid form.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  emulsion; formulation; immune response; lyophilization; vaccine adjuvants

Mesh:

Substances:

Year:  2017        PMID: 28259764     DOI: 10.1016/j.xphs.2017.02.024

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant.

Authors:  Kendall B Preston; Teri Ann S Wong; Albert To; Taylor E Tashiro; Michael M Lieberman; Alex Granados; Karen Feliciano; John Harrison; Jake Yalley-Ogunro; Hanne Andersen Elyard; Oreola Donini; Axel T Lehrer; Theodore W Randolph
Journal:  Vaccine       Date:  2021-08-13       Impact factor: 4.169

2.  Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Authors:  Ryan M Kramer; Michelle C Archer; Mark T Orr; Natasha Dubois Cauwelaert; Elyse A Beebe; Po-Wei D Huang; Quinton M Dowling; Alicia M Schwartz; Dawn M Fedor; Thomas S Vedvick; Christopher B Fox
Journal:  Int J Nanomedicine       Date:  2018-06-26

Review 3.  Development of thermostable vaccine adjuvants.

Authors:  Yizhi Qi; Christopher B Fox
Journal:  Expert Rev Vaccines       Date:  2021-06-26       Impact factor: 5.683

4.  Preparation of Squalene Oil-Based Emulsion Adjuvants Employing a Self-Emulsifying Drug Delivery System and Assessment of Mycoplasma hyopneumoniae-Specific Antibody Titers in BALB/c Mice.

Authors:  Rakesh Bastola; Jo-Eun Seo; Taekwang Keum; Gyubin Noh; Jae Woong Choi; Jong Il Shin; Ju Hun Kim; Sangkil Lee
Journal:  Pharmaceutics       Date:  2019-12-10       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.